ArticleTrials2025
Effects of Jinhua instant dark tea in patients with type 2 diabetes mellitus: study protocol for a multicenter, open-label, randomized controlled trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsThe global prevalence of diabetes is rising, with many patients experiencing challenges in medication adherence and adverse effects associated with synthetic drugs. Natural products have attracted interest as potential preventive or adjunctive therapies. Jinhua dark tea (JHTea), a naturally fermented Chinese tea, has shown promising glucose-lowering and lipid-modulating effects in vitro and animal studies, but robust clinical evidence is lacking. This study is the first large-scale, long-term randomized controlled trial (RCT) evaluating JHTea as an adjunctive therapy for type 2 diabetes mellitus (T2DM).
methodsThis multicenter, open-label parallel randomized controlled trial across three centers in China will enroll 264 participants aged 40-70 years with T2DM, excluding those with gastrointestinal diseases or acute diabetes-related complications. Participants will be randomized 1:1 to the following: (1) intervention Group: 1 g of JHTea three times daily plus current oral hypoglycemic agents for 12 months. (2) control Group: warm water plus current oral hypoglycemic agents alone, with no extra active intervention. The primary outcome is the change in hemoglobin A1c (HbA1c) at 6 months. Secondary outcomes at 6 and 12 months include diabetes remission rate, fasting plasma glucose (FPG), 2-h postprandial glucose, triglyceride-glucose index (TyG), blood pressure, abdominal circumference, body mass index (BMI), and other metabolic parameters. DISCUSSION: This study aims to investigate the glycemic and lipid-modulating effects of Jinhua instant dark tea in patients with T2DM. The findings may support the adjunctive role of fermented Jinhua tea in diabetes management, providing a complementary strategy to conventional therapies.
trial registrationChinese Clinical Trial Registry ChiCTR2400080339. Registered on 26 January 2024. https://www.chictr.org.cn/showproj.html?proj=214179.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.